CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Radionuclide Image-Guided Repair of the Heart Left Ventricular Assist Devices for Lifelong Support Association of Thrombus Aspiration With Time and Mortality Among Patients With ST-Segment Elevation Myocardial Infarction: A Post Hoc Analysis of the Randomized TOTAL Trial Coronary flow velocity reserve predicts adverse prognosis in women with angina and noobstructive coronary artery disease: resultsfrom the iPOWER study 稳定性冠心病诊断与治疗指南 Cardiovascular Biomarkers and Imaging in Older Adults: JACC Council Perspectives 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-label, randomized superiority trial

Original Research

JOURNAL:CBSMD Article Link

Percutaneous Left Atrial Appendage Occlusion: How Much Do We Know?

CBSMD

Pre-reading

  • Definition of percutaneous left artrail appendage occlusion
  • Indications for LAAO therapy

  • How to define study endpoints, stroke and classifications, transient ischemic attack, cardiovascular mortality, non-cardiovascular mortality, procedural mortality, immediate procedural mortality, systemic embolism, pericardial effusion, bleeding events etc.  




RCTs


Year 2009, "Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial"

confirmed the efficacy of percutaneous closure of the LAA with this device was non-inferior to that of warfarin therapy. Although there was a higher rate of adverse safety events in the intervention group than in the control group, events in the intervention group were mainly a result of periprocedural complications. Closure of the LAA might provide an alternative strategy to chronic warfarin therapy for stroke prophylaxis in patients with non-valvular atrial fibrillation.